Vote Scores

Home / Companies / Denali Therapeutics Inc. / 3 Jun 2025

Meeting · year to 30 June 2025367 filers reporting

Denali Therapeutics Inc.: meeting of 3 Jun 2025

Votes reported on Form N-PX, item by item

367 Form N-PX filers reported votes at the Denali Therapeutics Inc. meeting of 3 Jun 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

3 nominees; 61.3% of reported votes for; 112 filers withheld from or voted against at least one nominee.

795 vote records from 129 filers. 25 of the 129 filers that marked the item either way voted against management.

78.3% for0.0% against21.7% other19.4% against management129 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

566 vote records from 365 filers. 30 of the 353 filers that marked the item either way voted against management. 12 filers reported this item without a management mark.

87.7% for7.4% against4.9% other8.5% against management365 filers90.9% for9.1% against0.0% other9.1% against management159,967,668 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

265 vote records from 129 filers. 3 of the 129 filers that marked the item either way voted against management.

96.9% for1.6% against1.6% other2.3% against management129 filers99.9% for0.1% against0.1% other0.1% against management58,029,086 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityForForFor
DimensionalAbstain or withhold *ForFor
State Street and SPDRAbstain or withhold *ForFor
American CenturyForForFor
Franklin TempletonAbstain or withhold *ForFor
InvescoForForFor
EquitableAbstain or withhold *ForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsForForFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertAbstain or withhold *ForFor
J.P. MorganAbstain or withhold *ForFor
Goldman SachsForForFor
PGIM and PrudentialAbstain or withhold *ForFor
Jackson National fundsForForFor
Northern Trust and FlexSharesAbstain or withhold *ForFor
SEIForForFor
T. Rowe PriceForForFor
ThriventForForFor
Lincoln FinancialAbstain or withholdForFor
VoyaAbstain or withhold *ForFor
First TrustNo reportForNo report
NationwideForForFor
Victory CapitalForForFor
Brighthouse FundsForForFor
Guggenheim and RydexForForFor
Columbia ThreadneedleForForFor
BNY MellonForForFor
PrincipalForForFor
Capital Group and American FundsForAgainst *For
Pacific Life fundsForForFor
Global XForForFor
TransamericaForForFor
AllianceBernsteinAbstain or withhold *ForFor
DWSAbstain or withhold *ForFor
AllspringAbstain or withhold *ForFor
MassMutualForForFor
Neuberger BermanNo reportForNo report
Natixis and Loomis SaylesNo reportForNo report
Artisan PartnersForForFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Denali Therapeutics Inc. meeting?

367 Form N-PX filers reported votes at the meeting of 3 Jun 2025. On say-on-pay, 30 of 353 voted against management (8.5%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Denali Therapeutics Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Denali Therapeutics Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Denali Therapeutics Inc. with a meeting date within three days of 3 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.